width=Gene therapy, one of the most promising approaches now being tested on a range of rare and single-gene diseases, relies on using a modified virus to deliver a functioning copy of a gene into the cells of patients.

But the viruses that work best for delivering genes to the brain, called adeno-associated viruses (AAVs), are limited in the size of the gene that can be carried inside them. And unfortunately, the A-T gene is nearly two times larger than the largest gene that an AAV virus can carry. Scientists have tried engineering a smaller version of the A-T gene by removing parts of it, but they’re now convinced that the entire gene needs to be included to restore function.

To overcome this obstacle, the A-T Children’s Project has just funded the laboratory of James Dixon, PhD, from the University of Nottingham in the UK to develop a gene therapy approach for A-T based on nanotechnology that does not require using a virus. If Dr. Dixon’s team succeeds, their “non-viral” delivery system will be able to carry an entire A-T gene and may enable the treatment of all A-T patients, regardless of the type of mutations they carry.

Dr. Dixon’s work will be getting underway in the fourth quarter of this year and we expect to know, in an animal model, if his approach may work for A-T by late 2019.

Contact Us

Related News

Feb 23 @ 4:01 am

Looking Forward to Research Advances in 2024

Dear Friends, As 2023 is wrapping up, we want to thank all of you who support the A-T…

more
Feb 23 @ 4:01 am

A-T Biomarker Development Initiative Now Recruiting

On December 18, the A-T Children’s Project sent out the below email to A-T parents in the United…

more
Feb 23 @ 4:01 am

A-T Caregiver Weekend 2024 Announced

On December 15, the A-T Children’s Project sent the below email to parents inviting them to join us…

more
Feb 23 @ 4:01 am

Giving Tuesday Update 2023

It’s Giving Tuesday, and anonymous donors have joined together to match the first $60,000 in donations we receive!

more